Skip to main content
Premium Trial:

Request an Annual Quote

InforSense, GenomeQuest, Vanderbilt University, Proteus, Bristol Myers Squibb, GeneGo, Cambridge Cell Networks, University of Surrey, CCnet, Biobase, Integrated Genomics, Progeniq, Microsoft, ExonHit Therapeutics, Ariadne Pathway Studio, Yale University,

InforSense and GenomeQuest To Integrate and Sequence Search Software
InforSense and GenomeQuest will integrate technologies for better probing of data and sharing of work processes across research domains. GenomeQuest has also joined the InforSense Open Workflow Partner Network.
The companies said they expect the integration of GenomeQuest’s platform for analyzing sequence-based biological and patent content with InforSense’s workflow-based analytics to be of interest to attorneys, researchers, and business managers.
InforSense customers will be able to access GenomeQuest’s sequence and patent record databases directly through the InforSense platform via a node that sends data requests to the GenomeQuest sequence software.

Vanderbilt University’s Jim Ayers Institute Installs Proteus to Manage Cancer Research Data
GenoLogics, a developer of lab and data management software for life science researchers, said this week that Vanderbilt University’s Jim Ayers Institute for Precancer Detection and Diagnosis has implemented its Proteus laboratory and data management solution. Proteus will help the Ayers Institute in its research focused on early identification and treatment of colorectal cancer.
The institute’s research involves extensive clinical trials with thousands of participants at centers across the US, necessitating effective sample tracking and data storage
Proteus affords researchers the ability to create elaborate searches and perform data comparisons involving disease states and tissue proteotypes, the company said.

Bristol Myers Squibb Licenses GeneGo’s Software Suite and Databases
GeneGo has licensed its technology to Bristol-Myers Squibb, where reserchers will have the ability to start with chemical compound structures and/or genomics data to address questions from both chemistry and biology domains, the company said this week.
Bristol-Myers Squibb can also access GeneGo tools to build canonical pathway maps using public, GeneGo, and proprietary data.

Cambridge Cell Networks, UK, University of Surrey to use CCnet’s ToxWiz
Cambridge Cell Networks, an in-silico systems biology and toxicology company, said this week that the University of Surrey, UK will use CCnet's ToxWiz software for research on drug and chemical safety.
ToxWiz is a solution for predicting toxic endpoints and elucidating mechanisms of toxicity. It contains a network of more than 2,500 annotated pathways and clusters linking genomics and proteomics data with biochemical pathways and cellular information. It allows users to understand on- and off- target mechanisms of action of compounds, thus minimizing the number of animal testing wherever possible, the company said.

Biobase and Integrated Genomics Ink Curation Agreement
Biobase will curate and expand Integrated Genomics' ERGO database of microbial genomics information under a collaboration agreement, the companies said in a statement this week.
Biobase staff based in Bangalore, India, will add manually curated functional gene annotations and pathways to the ERGO database, which currently holds more than 3.1 million non-redundant gene sequences from more than 1,200 microbial genomes and around 6,300 biological pathways.
Biobase is based in Wolffenbuttel, Germany and has offices in Beverly, Mass., as well as in Bangalore.
Financial terms of the agreement were not released.

Progeniq joins Microsoft in Bio IT Alliance
Progeniq, a reconfigurable computing applications company headquartered in Singapore, said this week that it has joined the Microsoft-led BioIT Alliance.
The focus of the alliance is to integrate science and technology to accelerate the pace of drug discovery and realize the potential of personalized medicine. Early in its work, the alliance addressed data-capture and data-integration
challenges that face the industry.
Progeniq BioBoost is a hardware-accelerated platform for computationally intensive bioinformatics applications such as NCBI BLAST, Smith-Waterman, HMMer, and ClustalW.

ExonHit Therapeutics Extends its License for Ariadne Pathway Studio
Ariadne said this week that ExonHit Therapeutics has extended its license of Pathway Studio. ExonHit uses proprietary technology and Pathway Studio to research alternative RNA splicing in collaboration with drug development partners.
Pathway Studio extracts functional relationships of genes, proteins, small molecules, cell processes, diseases, among other criteria from scientific literature and delivers it via a database for computational analysis of experimental data interpretation.
"We integrate Pathway Studio into our processes for target discovery in order to identify pathways of interest and to prioritize splicing events that we will explore further in our research programs," said John Jaskowiak, executive vice president of business development at ExonHit, in a statement.
Pathway Studio comes with the ResNet database of more than 1.25 million functional relationships extracted from PubMed, and the MedScan module for automatic PubMed processing and information extraction. It is available as a Windows and web-based application and scales from a single-user desktop through enterprise-wide installation.

YaleUniversity Adopts Biotique XRAY for Microarray Analysis
Biotique Systems said this week that Yale University has licensed XRAY, its gene expression analysis system for analyzing Affymetrix microarrays.
"We find that XRAY is an intuitive and powerful tool for the analysis of Affymetrix Exon Array data," said Shrikant Mane, director of the Microarray Resource in the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale, in a statement.

NCI Renews Site License for Partek Genomics Suite
The National Cancer Institute has renewed its Partek Genomics Suite site-wide multi-license agreement, Partek said this week.
Researchers at the NCI will use Partek GS to analyze and visualize microarray data from studies done in cancer research. The renewed agreement continues to make Partek GS available to every researcher at the NCI.
Partek Genomics Suite is a statistical and visual data analysis software package that can handle thousands of samples and millions of variables in a genomics experiment, the company said.
The intuitive task specific workflows, recently introduced in the software, guide users through the import, analysis, and visualization of their data. Additional features include detection and display of alternative splice events, exon-level and copy number alterations, and mapping sites of protein/DNA interaction in ChIP-on-Chip visualization within the Genome Browser, as well as import and annotation capabilities for two-color arrays.

Sanofi-Aventis Renews Licenses for Genomatix Chip Analysis Pipeline
Sanofi-Aventis has renewed its licenses for multi-site access to the Genomatix Microarray Analysis Pipeline, Germany said this week.
The pipeline provides a fully integrated solution for analyzing expression and tiling microarray experiments, including the powerful ChIP-on-chip studies.
The Genomatix software module ChipInspector integrates with additional modules from the company, such as BiblioSphere PathwayEdition, ElDorado, and GEMS Launcher.

81qd Deploys Linguamatics I2E for Life Cycle Management Planning
Linguamatics, which offers natural language processing technology for life science research, has announced that 81qd, a New York City-based healthcare technologyconsultancy, has deployed Linguamatics’ flagship I2E.
The software will allow 81qd to support its life cycle management planning and related efforts.
In a company statement, 81qd’s executive vice president, Aafia Chaudhry, touted the solution as being “intuitive” and “easy to use” for biomedical literature mining.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.